These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3208421)

  • 1. Detection of platelet-activating factor during traumatic shock.
    Stahl GL; Craft DV; Lento PH; Lefer AM
    Circ Shock; 1988 Nov; 26(3):237-44. PubMed ID: 3208421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.
    Karasawa A; Rochester JA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1990 May; 12(4):231-7. PubMed ID: 2165204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.
    Lefer AM
    Crit Care Clin; 1989 Apr; 5(2):331-52. PubMed ID: 2650821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
    Toth PD; Mikulaschek AW
    Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Involvement of platelet activating factors in pathologic leukocyte-endothelium interactions in the liver after hemorrhagic shock].
    Marzi I; Bauer M; Reisdorf E; Walcher F
    Zentralbl Chir; 1994; 119(11):814-21. PubMed ID: 7846961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
    Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
    J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adrenal steroids in the recovery from platelet activating factor challenge.
    Myers AK; Bader TJ
    Circ Shock; 1987; 23(2):143-50. PubMed ID: 3677334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The physiopathology of acute pancreatitis: the role of platelet-activating factor (PAF)].
    Ais JG; Novo C; Gómez-Garre M; López-Farre A; López-Novoa JM; Romeo JM
    Rev Esp Enferm Dig; 1992 Jan; 81(1):25-8. PubMed ID: 1547030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE.
    Mencia-Huerta JM; Lewis RA; Razin E; Austen KF
    J Immunol; 1983 Dec; 131(6):2958-64. PubMed ID: 6315819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
    Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL; Bitterman H; Lefer AM
    Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyltransferase activity in isolated rat kidney cells.
    Pirotzky E; Ninio E; Bidault J; Pfister A; Benveniste J
    Lab Invest; 1984 Nov; 51(5):567-72. PubMed ID: 6492758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of a new LTD4 antagonist (LY-171883) in traumatic shock.
    Hock CE; Lefer AM
    Circ Shock; 1985; 17(4):263-72. PubMed ID: 3841503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activating factor (PAF) increases plasma protein extravasation and induces lowering of interstitial fluid pressure (P) in rat skin.
    Iversen VV; Nedrebø T; Borge BA; Salvesen GS; Reed RK
    Acta Physiol Scand; 2005 Sep; 185(1):5-12. PubMed ID: 16128692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):341-7. PubMed ID: 3116357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.